QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook

Qiagen (QGEN) Tops Q3 EPS by 8c

November 7, 2022 4:06 PM EST

Qiagen (NYSE: QGEN) reported Q3 EPS of $0.53, $0.08 better than the analyst estimate of $0.45. Revenue for the quarter came in at $500 million versus the consensus estimate of $481.71 million.

GUIDANCE:

Qiagen sees FY2022 EPS of $2.40, versus the consensus of $2.21. Qiagen sees FY2022... More